Transaction DateRecipientSharesTypePriceValue
21st December 2020Ann Hanham3,200Open or private purchase$6.25$20,000.00
21st December 2020Scott Sukenick1,600Open or private purchase$6.25$10,000.00
21st December 2020Eric Francois600Open or private purchase$6.25$3,750.00
21st December 2020Brian Philippe Tinmouth8,000Open or private purchase$6.25$50,000.00
21st December 2020Steven C Gilman4,000Open or private purchase$6.25$25,000.00
21st December 2020Armando Anido5,000Open or private purchase$6.25$31,250.00
21st December 2020Gonzalez David Angulo1,600Open or private purchase$6.25$10,000.00
21st December 2020Marco Taglietti40,000Open or private purchase$6.25$250,000.00
21st December 2020Guy Macdonald8,000Open or private purchase$6.25$50,000.00
25th November 2020Eric Francois3,480Payment by withholding$6.81$23,698.80
Scynexis logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

SCYNEXIS, Inc. is a biotechnology company. It engages in the development of novel oral and intravenous triterpenoid antifungal.

Ticker: SCYX
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1178253
Employees: 27
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $34 M (0%)
Other Assets, Current: $863 Th (28%)
Assets, Current: $41 M (-22%)
Property, Plant and Equipment, Net: $354 Th (-12%)
Other Assets, Noncurrent: $812 Th (0%)
Assets: $45 M (-20%)
Accounts Payable, Current: $5 M (-32%)
Accrued Liabilities, Current: $2 M (0%)
Liabilities, Current: $7 M (-33%)
Liabilities: $39 M (-12%)
Common Stock, Shares, Issued: $10 M (0%)
Retained Earnings (Accumulated Deficit): $285 M (0%)
Stockholders' Equity (Parent): $6 M (0%)
Liabilities and Equity: $45 M (-20%)
Revenue: $57 Th (-52%)
Research and Development: $8 M (-53%)
Operating Income/Loss: $12 M (-51%)
Other Income, net: $2 M (-70%)
Provision for income taxes: $3 M (0%)